EVE Health Group Limited, together with its subsidiaries, engages in the development, retail, and commercialization of health and wellness, and pharmaceutical products. The company lead product is Dyspro, a proprietary pharmaceutical-grade formulation to address dysmenorrhea (menstrual pain); and Libbo, a proprietary pharmaceutical-grade oral dissolving film formulation for the treatment of erectile dysfunction. It also offers Lactobacillus rhamnosus Beebiotic MAP01, a proprietary strain to support digestive health and vitality. The company was formerly known as EVE Investments Limited. EVE Health Group Limited was incorporated in 2003 and is based in Subiaco, Australia.